NGM Biopharmaceuticals IncNASDAQ:NGM
- LAST PRICE13.7400
- TODAY'S CHANGE (%)-0.1100 (-0.7942%)
- Bid / Lots10.4100/ 1
- Ask / Lots16.4900/ 1
- Open / Previous Close13.8900 / 13.8500
- Day Range
- 52 Week Range
- Volume196,938
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NGM |
|---|---|---|
| 09:32 ET | 3142 | 13.625 |
| 09:34 ET | 200 | 13.75 |
| 09:36 ET | 100 | 13.68 |
| 09:38 ET | 607 | 13.74 |
| 09:39 ET | 200 | 13.77 |
| 09:41 ET | 200 | 13.78 |
| 09:45 ET | 300 | 13.96 |
| 09:48 ET | 100 | 13.96 |
| 09:50 ET | 100 | 13.95 |
| 09:52 ET | 100 | 13.95 |
| 09:54 ET | 300 | 14.04 |
| 09:56 ET | 100 | 14.08 |
| 09:57 ET | 795 | 13.94 |
| 10:03 ET | 400 | 13.9 |
| 10:06 ET | 408 | 13.85 |
| 10:08 ET | 400 | 13.83 |
| 10:12 ET | 1539 | 13.81 |
| 10:14 ET | 400 | 13.77 |
| 10:15 ET | 200 | 13.84 |
| 10:21 ET | 200 | 13.88 |
| 10:24 ET | 100 | 13.77 |
| 10:26 ET | 320 | 13.74 |
| 10:28 ET | 373 | 13.68 |
| 10:30 ET | 2000 | 13.555 |
| 10:32 ET | 500 | 13.715 |
| 10:33 ET | 500 | 13.84 |
| 10:37 ET | 100 | 13.76 |
| 10:39 ET | 700 | 13.72 |
| 10:42 ET | 100 | 13.765 |
| 10:48 ET | 1100 | 13.75 |
| 10:50 ET | 412 | 13.78 |
| 10:51 ET | 200 | 13.85 |
| 10:53 ET | 359 | 13.855 |
| 10:57 ET | 100 | 13.735 |
| 11:00 ET | 1073 | 13.64 |
| 11:02 ET | 293 | 13.77 |
| 11:04 ET | 100 | 13.645 |
| 11:06 ET | 300 | 13.76 |
| 11:08 ET | 200 | 13.8 |
| 11:09 ET | 900 | 13.77 |
| 11:11 ET | 508 | 13.6925 |
| 11:13 ET | 100 | 13.715 |
| 11:15 ET | 300 | 13.69 |
| 11:18 ET | 400 | 13.68 |
| 11:20 ET | 400 | 13.705 |
| 11:22 ET | 200 | 13.62 |
| 11:24 ET | 500 | 13.63 |
| 11:26 ET | 300 | 13.685 |
| 11:27 ET | 200 | 13.665 |
| 11:31 ET | 500 | 13.7 |
| 11:33 ET | 500 | 13.784 |
| 11:36 ET | 500 | 13.77 |
| 11:38 ET | 100 | 13.85 |
| 11:40 ET | 200 | 13.84 |
| 11:42 ET | 300 | 13.74 |
| 11:44 ET | 100 | 13.78 |
| 11:45 ET | 300 | 13.77 |
| 11:47 ET | 200 | 13.77 |
| 11:49 ET | 100 | 13.72 |
| 11:54 ET | 200 | 13.74 |
| 11:56 ET | 100 | 13.78 |
| 12:02 ET | 400 | 13.71 |
| 12:03 ET | 100 | 13.735 |
| 12:05 ET | 2624 | 13.81 |
| 12:07 ET | 400 | 13.85 |
| 12:09 ET | 400 | 13.89 |
| 12:12 ET | 600 | 13.965 |
| 12:14 ET | 500 | 13.91 |
| 12:16 ET | 200 | 13.91 |
| 12:18 ET | 1756 | 13.8 |
| 12:20 ET | 449 | 13.795 |
| 12:21 ET | 400 | 13.845 |
| 12:23 ET | 100 | 13.87 |
| 12:25 ET | 500 | 13.93 |
| 12:30 ET | 3500 | 13.92 |
| 12:32 ET | 200 | 13.88 |
| 12:34 ET | 300 | 13.92 |
| 12:36 ET | 200 | 13.96 |
| 12:39 ET | 100 | 13.99 |
| 12:41 ET | 200 | 13.91 |
| 12:43 ET | 2944 | 13.94 |
| 12:48 ET | 700 | 13.97 |
| 12:50 ET | 4137 | 13.99 |
| 12:52 ET | 500 | 13.98 |
| 12:54 ET | 200 | 13.9 |
| 12:56 ET | 600 | 13.865 |
| 12:57 ET | 100 | 13.9 |
| 12:59 ET | 400 | 13.89 |
| 01:01 ET | 300 | 13.89 |
| 01:03 ET | 340 | 13.895 |
| 01:06 ET | 1520 | 13.915 |
| 01:08 ET | 200 | 13.93 |
| 01:12 ET | 400 | 13.915 |
| 01:15 ET | 1500 | 13.91 |
| 01:17 ET | 1500 | 13.911 |
| 01:19 ET | 395 | 13.91 |
| 01:28 ET | 900 | 14.02 |
| 01:30 ET | 100 | 13.98 |
| 01:32 ET | 400 | 14.02 |
| 01:39 ET | 100 | 13.98 |
| 01:42 ET | 500 | 13.96 |
| 01:44 ET | 100 | 13.98 |
| 01:48 ET | 300 | 14 |
| 01:51 ET | 904 | 13.965 |
| 01:53 ET | 400 | 13.98 |
| 01:55 ET | 100 | 14.02 |
| 01:57 ET | 200 | 13.99 |
| 02:00 ET | 100 | 14 |
| 02:04 ET | 100 | 14 |
| 02:06 ET | 200 | 13.99 |
| 02:09 ET | 200 | 14.01 |
| 02:11 ET | 310 | 14 |
| 02:18 ET | 100 | 13.99 |
| 02:22 ET | 309 | 14 |
| 02:24 ET | 200 | 13.98 |
| 02:29 ET | 300 | 13.96 |
| 02:31 ET | 200 | 13.96 |
| 02:36 ET | 1378 | 13.8804 |
| 02:38 ET | 300 | 13.91 |
| 02:42 ET | 600 | 13.86 |
| 02:44 ET | 1000 | 13.9 |
| 02:45 ET | 1772 | 13.96 |
| 02:47 ET | 566 | 13.96 |
| 02:49 ET | 876 | 13.9 |
| 02:51 ET | 355 | 13.92 |
| 02:54 ET | 300 | 13.88 |
| 02:58 ET | 500 | 13.87 |
| 03:00 ET | 300 | 13.85 |
| 03:02 ET | 105 | 13.86 |
| 03:05 ET | 100 | 13.87 |
| 03:07 ET | 200 | 13.83 |
| 03:12 ET | 850 | 13.83 |
| 03:14 ET | 100 | 13.805 |
| 03:16 ET | 500 | 13.79 |
| 03:18 ET | 861 | 13.81 |
| 03:20 ET | 300 | 13.81 |
| 03:21 ET | 522 | 13.75 |
| 03:23 ET | 600 | 13.74 |
| 03:25 ET | 100 | 13.75 |
| 03:27 ET | 100 | 13.74 |
| 03:30 ET | 600 | 13.7 |
| 03:32 ET | 1104 | 13.73 |
| 03:34 ET | 731 | 13.77 |
| 03:36 ET | 813 | 13.76 |
| 03:38 ET | 850 | 13.715 |
| 03:39 ET | 2101 | 13.721 |
| 03:41 ET | 311 | 13.725 |
| 03:43 ET | 1004 | 13.71 |
| 03:45 ET | 629 | 13.71 |
| 03:48 ET | 2284 | 13.68 |
| 03:50 ET | 1385 | 13.63 |
| 03:52 ET | 1882 | 13.715 |
| 03:54 ET | 2016 | 13.71 |
| 03:56 ET | 2260 | 13.72 |
| 03:57 ET | 3030 | 13.71 |
| 03:59 ET | 4600 | 13.74 |
Today
Insider Buy: Ngm Biopharmaceuticals, from 5 hours ago by MT Newswires
5 hours ago by MT Newswires
May 16, 2022
Insider Buy: NGM Biopharmaceuticals, from 7:09AM ET on Monday May 16, 2022 by MT Newswires
7:09AM ET on Monday May 16, 2022 by MT Newswires
May 12, 2022
NGM Biopharmaceuticals Begins Early-Stage Trial of NGM438 for Advanced Solid Tumors; Shares Rise, from 10:25AM ET on Thursday May 12, 2022 by MT Newswires
10:25AM ET on Thursday May 12, 2022 by MT NewswiresBRIEF-NGM Bio Announces Initiation Of Phase 1/1B Clinical Study Of NGM438 For Treatment Of Advanced Solid Tumors, from 8:31AM ET on Thursday May 12, 2022 by Thomson Reuters
8:31AM ET on Thursday May 12, 2022 by Thomson ReutersNGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors, from 8:00AM ET on Thursday May 12, 2022 by GlobeNewswire
8:00AM ET on Thursday May 12, 2022 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NGM Biopharmaceuticals Inc | 1.1B | -8.5x | --- |
Somalogic Inc | 1.1B | -12.7x | --- |
Revance Therapeutics Inc | 1.0B | -3.3x | --- |
Allogene Therapeutics Inc | 1.1B | -3.4x | --- |
MannKind Corp | 929.4M | -11.1x | --- |
Revolution Medicines Inc | 1.2B | -5.9x | --- |
Company Information
NGM Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel, potentially life-changing medicines based on scientific understanding of key biological pathways underlying cancer, retinal diseases and liver and metabolic diseases. The Company’s robust portfolio of product candidates include NGM707, NGM831, NGM438, NGM120, NGM621, aldafermin and MK-3655. NGM707 is a dual antagonist monoclonal antibody that is designed to improve patient immune responses to tumors by inhibiting both Immunoglobulin-like transcript 2 (ILT2) and Immunoglobulin-like transcript 4 (ILT4). NGM831 is an antagonist antibody that is designed to block the interaction of Immunoglobulin-like transcript 3 (ILT3) with fibronectin, a key component of the tumor stroma, as well as other cognate ligands. NGM438 is an antagonist antibody that is designed to inhibit leukocyte-associated immunoglobulin-like receptor 1 (LAIR1) and promote anti-tumor immune responses.
Contact Information
- Headquarters
- 333 Oyster Point BlvdSOUTH SAN FRANCISCO, CA, United States 94080-1978
- Phone
- 650-243-5555
- Fax
- 650-583-1646
Executives
- Executive Chairman of the Board
- William Rieflin
- Chief Executive Officer, Director
- David Woodhouse
- Founder, Chief Scientific Officer, Director
- Jin-Long Chen
- Chief Financial Officer
- Siobhan Mangini
- Senior Vice President, Chief Compliance Officer, General Counsel, Secretary
- Valerie Pierce
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.1B |
|---|---|
Revenue (TTM) | $77.3M |
Shares Outstanding | 79.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-1.61 |
Book Value | $4.31 |
P/E Ratio | -8.5x |
Price/Sales (TTM) | 14.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -162.36% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
